- Home
- ARQT vs GYRE Comparison
ARQT vs GYRE Comparison
Compare ARQT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- GYRE
- Stock Information
- Founded
- ARQT 2016
- GYRE 2002
- Country
- ARQT United States
- GYRE United States
- Employees
- ARQT N/A
- GYRE N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- GYRE Health Care
- Exchange
- ARQT Nasdaq
- GYRE Nasdaq
- Market Cap
- ARQT 1.7B
- GYRE 897.1M
- IPO Year
- ARQT 2020
- GYRE N/A
- Fundamental
- Price
- ARQT $13.74
- GYRE $7.42
- Analyst Decision
- ARQT Strong Buy
- GYRE
- Analyst Count
- ARQT 6
- GYRE 0
- Target Price
- ARQT $18.80
- GYRE N/A
- AVG Volume (30 Days)
- ARQT 1.9M
- GYRE 253.7K
- Earning Date
- ARQT 08-13-2025
- GYRE 08-12-2025
- Dividend Yield
- ARQT N/A
- GYRE N/A
- EPS Growth
- ARQT N/A
- GYRE N/A
- EPS
- ARQT N/A
- GYRE 0.02
- Revenue
- ARQT $212,819,000.00
- GYRE $100,643,000.00
- Revenue This Year
- ARQT $61.15
- GYRE $21.04
- Revenue Next Year
- ARQT $37.98
- GYRE $89.64
- P/E Ratio
- ARQT N/A
- GYRE $93.77
- Revenue Growth
- ARQT 100.03
- GYRE N/A
- 52 Week Low
- ARQT $7.86
- GYRE $6.11
- 52 Week High
- ARQT $17.75
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ARQT 56.81
- GYRE 39.71
- Support Level
- ARQT $13.97
- GYRE $7.26
- Resistance Level
- ARQT $14.69
- GYRE $8.00
- Average True Range (ATR)
- ARQT 0.66
- GYRE 0.49
- MACD
- ARQT 0.12
- GYRE -0.07
- Stochastic Oscillator
- ARQT 78.87
- GYRE 10.36
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.